David Kao

Dr. Kao joined their team in 2021 as VP of Regulatory Affairs. He brings over 20 years of pharmaceutical industry experience in drug development, overseeing programs from initial IND submission to marketing registration and life-cycle management. Before Inhibrx, Dr. Kao served as a regulatory lead collaborating on the design of integrated development strategies to support global registration for novel therapies in the oncology, immunology, neurology, and cardiovascular therapeutic areas. He comes with considerable regulatory experience in the management of complex clinical programs and the preparation of regulatory marketing applications from global organizations including Eisai, Roche, Daiichi-Sankyo, and Celgene. He most recently served as Development Program Leader at BMS, responsible for the successful delivery of all aspects of drug development for a specific immunology project. Dr. Kao is a registered Pharmacist and received his BS in Pharmacy from Rutgers University, MBA in Marketing from Rutgers Business School, and PharmD from Shenandoah University.